EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unsaturated fatty acid perturbation combats emerging triazole antifungal resistance in the human fungal pathogen Aspergillus fumigatus

Cecilia Gutierrez-Perez iD, Charles Puerner iD, Jane T Jones, Sandeep Vellanki, Elisa M Vesely, Mark A Xatse, Andre F C Viera, Carissa P Olsen, Keren O Attiku, Steven Cardinale, Steven M Kwasny, Narendran G-Dayanandan und 2 weitere

mBio · 17.07.2024 · 15 (7)

DOI: 10.1128/mbio.01166-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 17.07.2024. Verfasst von Cecilia Gutierrez-Perez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology and Immunology Department, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA. Hauptthemen laut MEDLINE: Aspergillus fumigatus, Antifungal Agents, Triazoles, Drug Resistance, Fungal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ORFDO NIH HHS, NIGMS NIH HHS, NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Contemporary antifungal therapies utilized to treat filamentous fungal infections are inhibited by intrinsic and emerging drug resistance. Consequently, there is an urgent need to develop novel antifungal compounds that are effective against drug-resistant filamentous fungi. Here, we utilized an Aspergillus fumigatus cell-based high-throughput screen to identify small molecules with antifungal activity that also potentiated triazole activity. The screen identified 16 hits with promising activity against A. fumigatus . A nonspirocyclic piperidine, herein named MBX-7591, exhibited synergy with triazole antifungal drugs and activity against pan-azole-resistant A. fumigatus isolates. MBX-7591 has additional potent activity against Rhizopus species and CO 2 -dependent activity against Cryptococcus neoformans . Chemical, genetic, and biochemical mode of action analyses revealed that MBX-7591 increases cell membrane saturation by decreasing oleic acid content. MBX-7591 has low toxicity in vivo and shows good efficacy in decreasing fungal burden in a murine model of invasive pulmonary aspergillosis. Taken together, our results suggest MBX-7591 is a promising hit with a novel mode of action for further antifungal drug development to combat the rising incidence of triazole-resistant filamentous fungal infections. IMPORTANCE The incidence of infections caused by fungi continues to increase with advances in medical therapies. Unfortunately, antifungal drug development has not kept pace with the incidence and importance of fungal infections, with only three major classes of antifungal drugs currently available for use in the clinic. Filamentous fungi, also called molds, are particularly recalcitrant to contemporary antifungal therapies. Here, a recently developed Aspergillus fumigatus cell reporter strain was utilized to conduct a high-throughput screen to identify small molecules with antifungal activity. An emphasis was placed on small molecules that potentiated the activity of contemporary triazole antifungals and led to the discovery of MBX-7591. MBX-7591 potentiates triazole activity against drug-resistant molds such as A. fumigatus and has activity against Mucorales fungi. MBX-7591’s mode of action involves inhibiting the conversion of saturated to unsaturated fatty acids, thereby impacting fungal membrane integrity. MBX-7591 is a novel small molecule with antifungal activity poised for lead development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aspergillus fumigatusAntifungal AgentsTriazolesDrug Resistance, FungalMicrobial Sensitivity TestsFatty Acids, UnsaturatedMiceAnimalsHumansHigh-Throughput Screening AssaysDrug SynergismRhizopusCryptococcus neoformansPiperidinesDisease Models, AnimalInvasive Pulmonary Aspergillosis

Stichwörter der Autor:innen

Aspergillus fumigatusantifungal agentsantifungal resistancefatty acidssterol regulatory element binding protein

Substanzen

Antifungal AgentsTriazolesFatty Acids, UnsaturatedPiperidines

Autor:innen und Institutionen

  • Microbiology and Immunology Department, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA.
  • Department of Chemistry and Biochemistry, Worcester Polytechnic Institute, Worcester, Massachusetts, USA.
  • Microbiotix Inc., Worcester, Massachusetts, USA.

ORCID-Profile: Cecilia Gutierrez-Perez, Charles Puerner, Timothy J Opperman, Robert A Cramer

Förderung

  • ORFDO NIH HHS
  • NIGMS NIH HHS
  • NIMHD NIH HHS
  • CLC NIH HHS
  • NIDDK NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Gutierrez-Perez, C., Puerner, C., Jones, J. T., Vellanki, S., Vesely, E. M., Xatse, M. A., Viera, A. F. C., Olsen, C. P., Attiku, K. O., Cardinale, S., Kwasny, S. M., G-Dayanandan, N., Opperman, T. J., & Cramer, R. A. (2024). Unsaturated fatty acid perturbation combats emerging triazole antifungal resistance in the human fungal pathogen Aspergillus fumigatus. mBio, 15(7). https://doi.org/10.1128/mbio.01166-24

Vancouver

Gutierrez-Perez C, Puerner C, Jones JT, Vellanki S, Vesely EM, Xatse MA, et al. Unsaturated fatty acid perturbation combats emerging triazole antifungal resistance in the human fungal pathogen Aspergillus fumigatus. mBio. 2024;15(7). doi:10.1128/mbio.01166-24

BibTeX
@article{GutierrezPerez2024,
  author = {Gutierrez-Perez, Cecilia and Puerner, Charles and Jones, Jane T and Vellanki, Sandeep and Vesely, Elisa M and Xatse, Mark A and Viera, Andre F C and Olsen, Carissa P and Attiku, Keren O and Cardinale, Steven and Kwasny, Steven M and G-Dayanandan, Narendran and Opperman, Timothy J and Cramer, Robert A},
  title = {Unsaturated fatty acid perturbation combats emerging triazole antifungal resistance in the human fungal pathogen Aspergillus fumigatus},
  journal = {mBio},
  year = {2024},
  volume = {15},
  number = {7},
  doi = {10.1128/mbio.01166-24}
}
Kostenlos starten →